Bucky you often make many good points that I agree with but your...

Bucky you often make many good points that I agree with but your latest post is just absurd and i think even you know it. You lose so much credibility with such poor thoughtless posts. Sometimes I just think you like to be the contrarian on HC.

Lets examine your comments:

1. It really amazes me how so many say they have faith in mpl and the data that has come from the trial but still say what a great job MT has done. This comments makes a lot of sense so not sure the purpose of it. Generally many SH commented that have great belief in the science and years of results but were disappointed with PAA's direction, promotion and marketing hence the stagnant SP. Now that changed since MT came on board and the vast majority are extremely happy with MT's performance and their paper profits. Your comment is reasonable and quite frankly is contrary to your thinking

2. MT wasn't here for the start of the trial nor for most of the trial it self so what has he actually done.
Have you been asleep for the past 7-months. MARKETING AND PROMOTIO, CR at no discount, formation of a world class scientific advisory board, upgrades management/executive team, introduces PAA interactive investor hub, enters new partnerships (Berry Consultant etc), engages with FDA, sets a concise pathway to commercialisation, releases clear and relevant investor presentations. I think even you were critical of the previous board and management for the lack of direction and in not promoting/marketing PAA/MPL. I could go on. In addition if you look at the SP chart since MT joined on 1 September 2023 the SP has risen 4.86 times from its price at 31 August 2023 of 7.3 cents to 35.5 cents at close at 8 April 2024. Ask your self again what has he done

3. From my point of view he failed to include any of the mnd data they had available when he submitted the ODD application.
What data are you talking about. I dot believe the end data prior to the top line results was appropriate for submission with the ODD application. Tell us all what was the downside of engaging with the FDA for the initial submission. Was there any? If so tell us all.

4. He has failed to progress the canine trial data to a deal.
I assume you mean progress the discussions that Roger was having. It's a stretch to put the blame on MT f there being n canine deal and as we all know progressing a canine deal was identified and a low priority in favour of mnd. This was made known and commented upon in the investor documents and presentations. Question for you: Would you rather MT chase a dog deal in favour of progressing mnd? Its been basically a 1-man show too give us all a break and take a reality check

5. He has failed to get a big pharma to put up any dollars
OMG what a ridiculous comment. When should have BP come to the party and splash the cash on PAA. Can you advise how many clinical stage biotechnology companies are out there and the number of deals done after a P1 trial. Regardless we have n idea (as it should be) of discussions going on behind the scene that may lead t a BP deal sme time in the future. You make it sound like P! complete where is BP with the cash. When were you expecting the big deal to be one and on what catalyst??

6. He has failed to even get the sp to remain above 50% of the independent valuation
The valuation is just a valuation, what hasn't PAA achieved its morningstar fair value estimate. As you would know investors assess rick, opportunity, progress and success differently. If it was that easy we would all be rich. It's hard sometimes to respond to such ridiculous statements because MT is not responsible for ensuring the SP reaches and stays at a SP set by an independent party. I dont think it's in his formal statement of duties and responsibilities but then again it wasn't drafted with your input. I shake my head at your comment.

7. So he has what has been called outstanding data which so far he has failed to do much with it.
I repeat myself since MT joined on 1 September 2023 the SP has risen 4.86 times from its price at 31 August 2023 of 7.3 cents to 35.5 cents at close at 8 April 2024. Ask your self again what has he done